SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell Technologies is trending as investors aggressively reposition for the AI hardware supercycle, with institutional flow intensifying ahead of upcoming earnings. The community is actively discussing the stock's role in the enterprise AI infrastructure buildout, while contrasting its valuation and integration strength against competitors in the data center space.

Starfighters Space, Inc. is engaged in the research and development of space flight, pilot training, and aeronautics programs. It operates the commercial fleet Lockhead F-104s. The company was founded by Rick Svetkoff on September 6, 2022 and is headquartered in Kennedy Space Center, FL.

Starfighters Space Inc

Starfighters Space Inc is drawing significant community attention as investors debate its long-term viability, potential share dilution, and the impact of leadership disputes following a recent private placement investment. While some bulls are betting on a recovery fueled by excitement around the broader space sector and upcoming high-profile industry events, skeptics are expressing concerns over financial transparency, the lack of immediate revenue, and potential insider selling.

Zoracles

Zoracles is currently capturing community attention as investors debate its long-term potential against a backdrop of broader crypto market volatility and the highly anticipated government policy changes. Discussion is heavily split between those focused on short-term accumulation during recent price dips and participants highlighting the project's creator-focused utility within the Base ecosystem as a catalyst for future growth.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is trending following the quiet launch of Meta's 'Forum' app, with the community actively debating whether this represents a true competitive threat or just another failed attempt at cloning the platform's unique discussion model. Investors remain divided as the stock faces continued volatility, with many analyzing the company's long-term growth prospects, user-generated data value, and recent competitive landscape shifts.

Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which focuses on the acquisition, development, and commercialization of branded prescription pharmaceutical products. Its products include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, Sancuso, Boxaban, Vasculan. Dyscorban, and RediTrex. The company was founded by A. J. Kazimi on January 7, 1999 and is headquartered in Nashville, TN.

Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals is currently a focal point for investors as it navigates a transition toward an orphan drug pipeline, centered on its ifetroban platform and an asset sale to Apotex. The community is actively discussing the stock's low float structure and upcoming catalyst milestones, such as clinical trial data updates and the progress of its regulatory roadmaps.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is capturing significant attention following stronger-than-expected prescription numbers for its oral Wegovy pill and an increased earnings outlook, signaling a potential turnaround for the firm. Community discussion is focused on the company's ability to maintain a competitive edge through its oral drug rollout, its aggressive pipeline expansion, and the potential impact of future business development and acquisitions on its long-term market position.

T1 Energy, Inc. engages in developing battery solutions. It focuses on energy storage systems and commercial mobility. The company was founded by Tom Einar Jensen, Peter Matrai, and Tore Ivar Slettemoen on August 31, 2023 and is headquartered in Austin, TX.

T1 Energy Inc.

T1 Energy is rallying on heavy volume following reports of significant institutional accumulation by Situational Awareness and analyst support, despite facing a short-seller attack that the community largely dismissed as a manipulation attempt. Investors are increasingly viewing the stock as a key infrastructure play tied to the massive power demands of AI data centers.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as investors react to strong Q1 results, characterized by a massive earnings and revenue beat driven by rapid demand for Zepbound and Mounjaro. The community is actively discussing the company's raised full-year guidance and the competitive implications of its expanding GLP-1 and oncology portfolios against key rivals like Novo Nordisk.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Enovix is currently trending as investors focus on the upcoming earnings report and the company's progress toward commercial scaling of its silicon-anode battery technology for wearables and drones. The community is actively debating the significance of recent leadership appointments and potential qualification updates, balancing long-term technological optimism against frustration over past project timelines and stock performance.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics is facing significant volatility following mixed phase 2 interim results for its inhaled cystic fibrosis therapy, ARCT-032, which showed mucus plug reduction but failed to meet expectations for rapid lung function improvement. While the community is actively debating whether the data represents a proof-of-concept success that warrants a longer treatment horizon or a failure to demonstrate efficacy, bulls are pointing to the company's solid cash position, CSL partnership, and the potential for better outcomes as trial doses increase.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Morgan Stanley Lowers Portillo's (NASDAQ:PTLO) Price Target to $6.00

Morgan Stanley reduced their price objective on shares of Portillo's from $7.00 to $6.00 and set an "equal weight" rating for the company in a research report on Wednesday...

Stifel Nicolaus Lowers Portillo's (NASDAQ:PTLO) Price Target to $5.00

Stifel Nicolaus lowered their target price on shares of Portillo's from $6.00 to $5.00 and set a "hold" rating on the stock in a report on Wednesday...

Piper Sandler Has Lowered Expectations for Portillo's (NASDAQ:PTLO) Stock Price

Piper Sandler decreased their price target on shares of Portillo's from $8.00 to $6.00 and set an "overweight" rating on the stock in a research note on Wednesday...

Portillo's Q1 Earnings Call Highlights

Portillo's (NASDAQ:PTLO) executives emphasized a renewed focus on operations, marketing, and disciplined unit development as the company reported first-quarter fiscal 2026 results that showed modest revenue growth, flat same-restaurant sales, and lower profitability.

New CEO outlines strategic prio...

Portillo's (NASDAQ:PTLO) Earns Equal Weight Rating from Stephens

Stephens restated an 'equal weight' rating and issued a $6.00 target price on shares of Portillo's in a report on Tuesday...

Portillo's (NASDAQ:PTLO) Announces Quarterly Earnings Results

Portillo's (NASDAQ:PTLO - Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.01) EPS for the quarter, missing analysts' consensus estimates of $0.01 by...

Portillo's Inc. (PTLO) Reports Q1 Loss, Lags Revenue Estimates

Portillo's Inc. (PTLO) delivered earnings and revenue surprises of -200.00% and -0.59%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

eBay Q1 Earnings & Revenues Surpass Estimates, Both Increase Y/Y

EBAY reports robust Q1 growth with higher revenues, expanding buyer base and strong ad performance driving earnings beat.


ETSY Q1 Earnings & Revenues Surpass Estimates, Both Increase Y/Y

ETSY delivers strong Q1 results, topping earnings and revenue estimates as advertising and services drive growth and margins improve.

Merchant Model Strength Powers BKNG's Q1 Earnings & Revenue Growth

BKNG's Q1 surge was fueled by booming merchant revenues, but a softer Q2 outlook signals slowing momentum.

Portillo's, Inc. operates a chain of fast-casual restaurants. Its menu includes hot dogs, Italian beef sandwiches, burgers, chicken sandwiches, salads, fries, shakes, and desserts. The company was founded in 1963 and is headquartered in Oak Brook, IL.

Current Price	$4.03
Prev Close	$4.10
Open	$4.06
Dividend Yield	0.00%
50-Day Moving Average	$5.30
Beta	1.07
Avg. Volume	1.31M
PE Ratio	18.20

52-Week High	$12.44
52-Week Low	$3.81
Market Capitalization	$310.8M
EPS (Annual)	$0.2721
Price to Book	0.62
Revenue Per Employee	$92,784.03

PTLO
Portillos Inc - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Latest PTLO News

PTLOPortillos Inc - Ordinary Shares - Class A